Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Innovent Biologics to Present Phase 3 Trial Results of Mazdutide at 2026 ADA Scientific Sessions

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

CMBC International and DBS Maintain Buy Rating for BeiGene

Jiayi Group's BD Project MAT2A Inhibitor Downgraded by BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

159849

512010

159992

159316

513700

159892

ARKG

159837

513060

516500

512290

516930

159570

Relay Therapeutics has launched a public offering of $175 million in common stock, with all shares sold by the company. Underwriters have a 30-day option to purchase an additional 15% of shares. Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities are the joint bookrunners. The offering is subject to market conditions.

PUBT

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Direxion S&P Biotech Bull 3X

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

iShares Biotechnology ETF

VG Health

iShares Global Healthcare

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

ChinaAMC CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Guotai CSI Bio-medicine ETF

iShares US Pharma

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ALPS Medical Breakthrough

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

VanEck Biotech ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Relay Therapeutics

Jefferies Financial

Goldman Sachs

GS Hldg R

Relay Therapeutics launches $175 million common stock offering

159859

Ipsen announced findings from the Phase IV DIRECTION trial comparing Dysport and Botox for upper limb spasticity. The results, presented at the ISPRM congress in Vancouver on May 19, 2026, showed Dysport had a similar safety profile to Botox and offered longer-lasting symptom relief.

Unusual Whales

Tianhong CNI BIOMEDICINE ETF

Proshares UltraShort Nasdaq Biotech

China Southern Hang Seng Biotech ETF(QDII)

Invesco Nasdaq Biotechnology ETF

BlackRock, Inc.

Penghua SSE STAR Biology and Medicine ETF

SPDR S&P Biotech

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity

On May 19, 2026, the leading sector was the Energy Select Sector SPDR ETF (XLE) with a price change of +0.22%. The Health Care Select Sector SPDR ETF (XLV) also gained slightly. Conversely, the Technology Select Sector SPDR ETF (XLK) led the losses with a decline of -1.95%, followed by the Industrial (XLI) and Consumer Discretionary (XLY) sectors. This data helps traders analyze market trends for better investment decisions.

benzinga_article

United States Oil Fund LP

Spdr Select Indu

ProShares Ultra Energy

SPDR S&P Software

iShares US Oil Equip & Svcs

SPDR Energy Select

Pro Ultr Bloomberg Crude Oil

SPDR O&G Ex & Prd

VG Energy

iShares US Medical Devices

ISHRS S&P Glb Engy

iShares Expanded Tech Software Sector ETF

SPDR S&P Health Equip

China Merchants CSI All Share Medical Apparatus and Instruments ETF

VanEck Oil Services ETF

Spdr Select Tech

SPDR FD Consumer Discretionary

Spdr Material

Real Est Select Spdr

Comm Servcies Select Sector SPDR

Financial Select Sector SPDR Fund

SPDR FD Consumer Staples

Leading And Lagging Sectors For May 19, 2026

01801

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

prnewswire

INNOVENT BIO

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

REMEGEN

RemeGen

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Microbiotica reports positive results for MB097 in advanced melanoma

China's 12th batch of centralized drug procurement will include over 70 varieties and 233 specifications, marking a record high. This batch introduces a pre-filing mechanism for transparency. Major drugs like Entresto, with annual sales of CNY8 billion, face intense competition. The new medical insurance policy limits reimbursements to procurement prices, influencing patient choices towards lower-priced options. The National Healthcare Security Administration plans to enhance procurement rules to foster competition among enterprises.

Yicai

China’s 12th Batch of Centralized Drug Procurement to Cover Record Number of Varieties

ZLAB

09688

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

China Universal 800 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF(159506.SZ)